Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies

Breast cancer is the second most leading cause of death among women. Multiple drugs have been approved by FDA for the treatment of BC. The major drawbacks of existing drugs are the development of resistance, toxicity, selectivity problem. The other therapies like hormonal therapy, surgery, radiotherapy, and immune therapy are in use but showed many side effects like bioavailability issues, non-selectivity, pharmacokinetic-pharmacodynamic problems. Therefore, there is an urgent need to develop new moieties that are nonviolent and more effective in the treatment of cancer. Isoxazole derivatives have gain popularity in recent years due to anticancer potential with the least side effects. These derivatives act as an anticancer agent with different mechanisms like inducing apoptosis, aromatase inhibition, disturbing tubulin congregation, topoisomerase inhibition, HDAC inhibition, and ER alpha inhibition. In this article, we have explored the synthetic strategies, anticancer mechanism of action along with SAR studies of isoxazole derivatives. (C) 2021 Elsevier Masson SAS. All rights reserved.

Automated summary

Breast cancer ranks as the second leading cause of death among women, with existing drug therapies facing issues like resistance and toxicity, highlighting the urgent need for the development of new, nonviolent treatment options for the disease. Isoxazole derivatives have gained attention in recent years for their anticancer potential with minimal side effects.